News
Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...
Zacks Investment Research on MSN2h
Merck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock?Merck MRK announced a definitive agreement to acquire Verona Pharma VRNA for approximately $10 billion. The deal will add ...
MONTCO Today on MSN4h
WSJ: Merck Makes $10 Billion Move as Keytruda Patent Expiration NearsMerck is making big pharma waves again with a $10 billion deal to acquire Verona Pharma, reports Colin Kellaher for the Wall ...
MRK banks on new launches as Keytruda faces a looming patent cliff and Gardasil weakens amid China's demand slump.
President Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S., but not immediately ...
Merck is a massive company with strong fundamentals and underlying value at a heavily discounted price. Click here to find ...
Merck (MRK) is spending about $10 billion to acquire Verona Pharma (VRNA) as the company looks to fill future revenue gaps.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback